Depakote Taper Schedule with Dates Starting Today
For a patient on Depakote 500 mg BID (1000 mg/day total), reduce by approximately 25% every 1-2 weeks using the following schedule:
Taper Schedule
Current Date: [Today's Date]
Weeks 1-2 (Today through [Date +2 weeks]):
- Reduce to 750 mg/day total
- Dosing: 500 mg AM, 250 mg PM
- This represents a 25% reduction from baseline 1
Weeks 3-4 ([Date +2 weeks] through [Date +4 weeks]):
- Reduce to 500 mg/day total
- Dosing: 250 mg BID (twice daily)
- This represents an additional 33% reduction 1
Weeks 5-6 ([Date +4 weeks] through [Date +6 weeks]):
- Reduce to 250 mg/day total
- Dosing: 250 mg once daily
- This represents a 50% reduction from previous dose 1
Weeks 7-8 ([Date +6 weeks] through [Date +8 weeks]):
- Discontinue completely
- Final taper from 250 mg to zero 1
Critical Monitoring Requirements
The FDA label explicitly states that antiepilepsy drugs should not be abruptly discontinued due to the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life 1. This 25% every 2 weeks reduction schedule aligns with FDA guidance for concomitant AED dosage reduction 1.
- Monitor closely for increased seizure frequency during each reduction phase 1
- The speed and duration of withdrawal can be highly variable and requires close patient monitoring 1
- If seizures recur during taper, consider slowing the reduction or returning to the previous effective dose 1
Important Caveats
- This taper schedule assumes the patient is clinically stable and discontinuation is medically appropriate 1
- Slower tapers (e.g., 10% per month) may be better tolerated in patients on long-term therapy, though specific evidence for valproate is limited 2
- Avoid alternate-day dosing strategies during taper, as this can cause significant fluctuations in drug levels and increase withdrawal symptoms 3
- Consider checking valproate levels if withdrawal symptoms emerge or seizures recur (therapeutic range 50-100 mcg/mL) 1